.png)
.png)
Latest news from BIA
BIA comment on NICE and NHS England’s decision to fund Novartis’ CAR-T therapy Kymriah
Commenting on NICE and NHS England’s decision to fund Novartis’ Kymriah for patients up to 25 years old with a certain type of leukemia, BIA CEO, Steve Bates, said: “Today’s decisions by NICE NHS England shows that the UK is well set to be the best country in the world in which to invent, trial, develop, manufacture and market next generation CAR-T cell cancer therapies.
BIA responds to UK Government letter to pharmaceutical industry on stockpiling medicines
The Department of Health has today written to pharmaceutical companies on the EU Exit – Human medicines supply in a March 2019 ‘no deal’ scenario. The letter details government contingency plans to stockpile medicines to cope with any potential delays at the border that may arise in the short term.
BIA responds to the release of Government technical notices on no deal Brexit
The UK Government has today released a series of 25 technical notices that offer guidance for business on what will happen in a ‘no deal’ Brexit. The notices were launched following a speech by Brexit Secretary Dominic Raab.
BioIndustry Association/Informa Biotech Financing Update shows strong venture capital fundraising by sector as momentum continues to build for biotech financing in 2018
The BIA/Informa Biotech Financing Update March-May 2018 released today shows that UK biotech companies’ ability to attract financing continues to build momentum after a solid start to the year.
Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.
Owlstone Medical Appoints Dr Andy Richards CBE to its Board of Directors
Owlstone Medical Ltd, a global diagnostics company developing a breathalyzer for early disease detection and precision medicine, announced today the addition of Dr Andy Richards CBE to its Board as a Non-Executive Director.
Domainex appoints Dr Trevor Perrior as Chief Executive Officer
Domainex Ltd, a privately-owned drug research services company, is pleased to announce the appointment of Dr Trevor Perrior as Chief Executive Officer, effective from 1st October 2018.
Novel deep learning drug discovery platform gets £1 million innovation boost
Funding to support Artificial Intelligence (AI) in drug discovery takes a significant step forward today as Optibrium™, Intellegens, and Medicines Discovery Catapult secure a grant from Innovate UK to fund a £1 million project.
CEO Update | Monday 24 September
It’s European Biotech week, part of global biotech week, do check out #biotechweek on twitter to see what’s going on. Here the UK sector goes from strength to strength. BIA member KalVista opened their new facility as anchor tenants at the Porton Science Park last week. It’s great to see a winner of the Biomedical Catalyst scaling and developing fantastically. With significant new funding via inward investment from the NASDAQ market last month KalVista are developing small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Congratulations are also due to member Cobra Biologics who were presented with the Queen’s Award 2018 for Enterprise, in the International Trade category on Thursday in recognition of their commercial s
Video of the week | The Industrial Strategy Challenge Fund
The Industrial Strategy Challenge Fund is transforming existing industries and creating entirely new ones.
UK life sciences and the changing commercial environment
The BIA has this week responded to two government consultations that are likely to have significant impacts on the commercial environment for medicines in England. Over the summer, the Department for Health and Social Care published consultations on proposed changes to the statutory pricing scheme for branded medicines and the introduction of regulations to allow NICE to charge companies for their health technology appraisal programme
CEO Update | Monday 17 September
A key part of the life sciences industrial strategy, the Novo Nordisk Research Centre opened in Oxford last Wednesday, which is focused on diabetes research. Work there will focus on deepening scientific understanding of diabetes, understanding the impact diabetes has on other health conditions, and analysing patient data to better understand and detect the onset of type II diabetes. The location of the centre will of course allow collaboration with the local ecosystem, tapping into its large talent pool and knowledge base.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector, BIA update: January - April 2018
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.
Biotech Financing Update: December 2017 to February 2018
The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.
Pipeline Progressing: The UK's Global Bioscience Cluster in 2017
A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.
BIA Best practice guide for communicating R&D
Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.
